Coeptis Therapeutics Inc (COEP)
Official siteBIOTECHNOLOGY
Last updated: Apr 24, 2026 at 5:00 PM ET
Coeptis Therapeutics Inc (COEP) Financials: Revenue, Profit and Cash Flow
Coeptis Therapeutics reported revenue of $1.36M for the fiscal year ended Dec 31, 2025. That year, net income was -$12.28M with a net margin of -900.7%, operating cash flow was -$8.60M and free cash flow was -$8.60M. The quarter ended Jun 30, 2026 had revenue of $3.17M and net income of -$27.52M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.36M | N/A | 86.7% | -956.9% | -900.7% |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2021 | $75.00K | N/A | 100.0% | -18727.9% | -17932.4% |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | N/A | N/A | N/A | N/A | N/A |
| Dec 2005 | N/A | N/A | N/A | N/A | N/A |
| Dec 2004 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2005 | Dec 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.36M | $0 | $0 | $0 | $75.00K | $0 | $0 | N/A | N/A | N/A |
| Cost of revenue | $180.63K | $0 | $0 | $0 | $0 | $0 | $0 | N/A | N/A | N/A |
| Gross profit | $1.18M | $0 | $0 | $0 | $75.00K | $0 | $0 | N/A | N/A | N/A |
| Research and development | $1.28M | $2.33M | $6.67M | $20.89K | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$13.04M | -$10.05M | -$21.49M | -$34.20M | -$14.05M | -$68.43K | -$2.23K | N/A | -$308.00K | -$10.08K |
| Net income | -$12.28M | -$10.88M | -$21.27M | -$37.57M | -$13.45M | -$17.28M | -$2.23K | -$7.07K | -$344.00K | $2.65M |
| EBITDA | -$9.82M | -$9.40M | -$20.12M | -$32.96M | -$13.81M | N/A | -$2.23K | -$7.07K | N/A | $2.65M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.17M | $113.77K | $862.05K | $237.44K | $0 | $62.87K | $1.86M | $0 | $0 | $0 | $1.50M | $0 |
| Gross profit | -$1.77M | $68.61K | $816.89K | $192.29K | $0 | $17.72K | -$259.98K | $0 | $0 | $0 | -$250.31K | $0 |
| Operating income | -$13.79M | -$3.91M | -$1.99M | -$2.48M | $0 | -$4.06M | -$2.16M | -$2.14M | -$2.83M | -$2.92M | -$3.37M | -$7.90M |
| Net income | -$27.52M | -$7.94M | -$1.62M | -$2.90M | $0 | -$6.78M | -$3.01M | -$1.83M | -$3.04M | -$3.00M | -$3.76M | -$6.35M |
Balance Sheet
As of Dec 2025, total debt of $250.00K exceeded cash and equivalents by $248.60K.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2005 | Dec 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.40K | $8.91M | $4.57M | $7.92M | $6.77M | $76.71M | $171.54K | $80.00K | $153.56K | $46.92K |
| Current assets | $1.40K | $1.05M | $1.75M | $3.94M | $2.18M | $959.00K | $505 | $1.22M | $153.56K | $383 |
| Cash and equivalents | $1.40K | $532.88K | $1.47M | $3.79M | $2.18M | $907.18K | $505 | N/A | $153.56K | $383 |
| Total liabilities | $120 | $5.04M | $3.76M | $3.46M | $4.41M | $22.95M | $155.85K | $62.07K | $705.22K | $310.94K |
| Short-term debt | $100.00K | $1.19M | $975.00K | $1.85M | $2.42M | $1.92M | $152.64K | $62.07K | $650.00K | $95.00K |
| Long-term debt | $150.00K | $150.00K | $150.00K | $150.00K | $1.65M | $150.00K | N/A | N/A | N/A | N/A |
| Shareholder equity | $1.28K | $3.38M | $813.96K | $4.45M | $2.35M | -$22.00M | $15.69K | $17.93K | -$551.66K | -$264.01K |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $134.51M | $19.79M | $19.84M | $14.18M | $12.19M | $13.45M | $8.91M | $8.96M | $4.20M | $3.89M | $7.16M | $4.67M |
| Total liabilities | $2.03M | $2.21M | $2.09M | $3.26M | $5.11M | $5.99M | $5.04M | $3.97M | $4.51M | $5.03M | $4.67M | $2.78M |
| Cash and equivalents | $15.49M | $5.21M | $5.67M | $4.91M | $2.00M | $4.27M | $532.88K | $1.14M | $1.56M | $1.03M | $3.24M | $1.41M |
| Shareholder equity | $132.48M | $17.18M | $17.25M | $10.37M | $6.10M | $6.48M | $3.19M | $4.82M | -$442.55K | -$1.14M | $2.49M | $1.89M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.60M | -$6.65M | -$7.24M | -$3.88M | -$4.49M | -$115.69K | -$1.78K | -$839.06K |
| Capital expenditures | $0 | $4 | $0 | $0 | $1.75M | $0 | $35 | $2.79K |
| Free cash flow | -$8.60M | -$6.65M | -$7.24M | -$3.88M | -$6.24M | -$115.69K | -$1.82K | -$841.85K |
| Dividends paid | N/A | N/A | N/A | N/A | $77.59K | N/A | N/A | N/A |
| Share repurchases | N/A | N/A | N/A | N/A | $247.16K | $324.98K | $88.28K | N/A |
| Investing cash flow | $0 | $0 | $0 | $0 | -$1.75M | -$75.75M | $0 | $632.87K |
| Financing cash flow | $13.74M | $5.71M | $4.92M | $5.49M | $8.22M | $76.77M | $2.29K | $594.08K |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.56M | -$1.76M | -$1.69M | -$2.15M | $2.37M | -$2.37M | -$1.44M | -$1.89M | -$1.42M | -$1.90M | -$1.69M | -$1.96M |
| Capital expenditures | N/A | N/A | $0 | $3 | $0 | $0 | $1 | $0 | $1 | $0 | $0 | $0 |
| Free cash flow | N/A | N/A | -$1.69M | -$2.15M | $2.37M | -$2.37M | -$1.44M | -$1.89M | -$1.42M | -$1.90M | -$1.69M | -$1.96M |
Frequently Asked Questions About COEP
What is Coeptis Therapeutics' annual revenue?
Coeptis Therapeutics reported revenue of $1.36M for the fiscal year ended Dec 31, 2025.
Is Coeptis Therapeutics profitable?
No. Coeptis Therapeutics reported net income of -$12.28M for the fiscal year ended Dec 31, 2025, with a net margin of -900.7%.
How much free cash flow does COEP generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$8.60M minus capital expenditures of $0 produced free cash flow of -$8.60M.
How much debt does Coeptis Therapeutics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $150.00K, short-term debt of $100.00K and cash and equivalents of $1.40K.
What is COEP's profit margin?
For the fiscal year ended Dec 31, 2025, Coeptis Therapeutics reported gross margin of 86.7%, operating margin of -956.9% and net margin of -900.7%.
COEP pages: Overview, Financials